Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
Why "Hims and Hers" Stock Plummeted
Description
The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight loss drug, Zepibound (Trizepatide). Despite Hims & Hers not selling Trizepatide but offering semaglutide, which remains in shortage, investor confusion and overreaction led to the stock decline. The video suggests that this reaction doesn't reflect the company's fundamentals and some see it as a buying opportunity.
More from User
00:52
ON Semi Buys Synaptics
Benzinga
00:55
Endless Shrimp Lawsuit
Benzinga
00:53
DOJ Settlement Push
Benzinga
00:51
Trump Limits GPT-5.6 Rollout
Benzinga
00:52
Bayer Wins Roundup Case
Benzinga
00:50
Micron’s $22B AI Bet
Benzinga
Related Videos
03:20
Stock Market Today: S&P 500, Dow Jones Futures Rise After Stellar October Gains— Micron Tech, Palantir, Hims & Hers In Focus
Benzinga
00:31
Hims & Hers Stock Rises 5% After Adding Zepbound And Mounjaro To Weight Loss Platform
Benzinga
03:35
Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike—Hims & Hers, Ovintiv, Uniqure In Focus
Benzinga
00:45
DJT Stock Has Plummeted 50% Since Trump's Inauguration But Investors Could Take Heart Its Fate Is Not As Bad As TRUMP Memecoin
Benzinga
01:08
Lululemon's Stock Plummeted Because its Spring Leggings are Boring
Buzz60
20:17
Hims and Hers CEO on Growth Beyond Sex Medication
Bullish Studio